share_log

180 Life Sciences | 424B3: Prospectus

180 Life Sciences | 424B3:募资说明书

美股SEC公告 ·  02/28 06:47

Moomoo AI 已提取核心信息

180 Life Sciences Corp. has announced a 1-for-19 reverse stock split of its common stock, effective as of 12:01 A.M. Eastern Time on February 28, 2024. This action is intended to satisfy the NASDAQ's minimum bid price requirement for continued listing. The reverse stock split will reduce the number of outstanding shares from approximately 11.3 million to about 0.6 million. No fractional shares will be issued; stockholders who would have received a fractional share will instead receive one whole share. The company's common stock will continue to trade on the NASDAQ under the symbol 'ATNF'. Prior to the reverse stock split, the company's stock was trading at $0.195 per share as of February 27, 2024. Additionally, the company has filed a prospectus supplement that updates...Show More
180 Life Sciences Corp. has announced a 1-for-19 reverse stock split of its common stock, effective as of 12:01 A.M. Eastern Time on February 28, 2024. This action is intended to satisfy the NASDAQ's minimum bid price requirement for continued listing. The reverse stock split will reduce the number of outstanding shares from approximately 11.3 million to about 0.6 million. No fractional shares will be issued; stockholders who would have received a fractional share will instead receive one whole share. The company's common stock will continue to trade on the NASDAQ under the symbol 'ATNF'. Prior to the reverse stock split, the company's stock was trading at $0.195 per share as of February 27, 2024. Additionally, the company has filed a prospectus supplement that updates and amends previous filings with the SEC, including information on the reverse stock split and recent Current Reports on Form 8-K. In other events, the company won a Motion for Partial Summary Judgment in a lawsuit, which obligates two insurers to advance defense costs related to SEC subpoenas to former executives, with a trial scheduled for May 12, 2025.
180 生命科学公司宣布对普通股进行1比19的反向分割,自美国东部时间2024年2月28日凌晨 12:01 起生效。该行动旨在满足纳斯达克继续上市的最低出价要求。反向股票拆分将使已发行股票的数量从约1130万股减少到约60万股。不会发行零碎股票;本来可以获得部分股份的股东将获得整股。该公司的普通股将继续在纳斯达克上市,股票代码为 “ATNF”。在反向股票拆分之前,截至2024年2月27日,该公司的股票交易价格为每股0.195美元。此外,该公司还提交了一份招股说明书补充文件,更新和修订了先前向美国证券交易委员会提交的文件,包括有关反向股票拆分的信息以及近期的8-K表最新报告。在其他事件中,该公司在一项诉讼中赢得了部分即决判决动议,该动议要求两家保险公司向前高管预付与美国证券交易委员会传票有关的辩护费用,审判定于2025年5月12日进行。
180 生命科学公司宣布对普通股进行1比19的反向分割,自美国东部时间2024年2月28日凌晨 12:01 起生效。该行动旨在满足纳斯达克继续上市的最低出价要求。反向股票拆分将使已发行股票的数量从约1130万股减少到约60万股。不会发行零碎股票;本来可以获得部分股份的股东将获得整股。该公司的普通股将继续在纳斯达克上市,股票代码为 “ATNF”。在反向股票拆分之前,截至2024年2月27日,该公司的股票交易价格为每股0.195美元。此外,该公司还提交了一份招股说明书补充文件,更新和修订了先前向美国证券交易委员会提交的文件,包括有关反向股票拆分的信息以及近期的8-K表最新报告。在其他事件中,该公司在一项诉讼中赢得了部分即决判决动议,该动议要求两家保险公司向前高管预付与美国证券交易委员会传票有关的辩护费用,审判定于2025年5月12日进行。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息